Market Overview

UPDATE: Credit Suisse Initiates Genomic Health at Outperform on Growth Potential

Related GHDX
CMS Increases Final Pricing Determination for Oncotype DX Breast Cancer Test to Previously Established Rate of $3,416
A Portfolio To Support Cancer Treatments In Time For Prostate Cancer Awareness Month

Credit Suisse initiated coverage on Genomic Health (NASDAQ: GHDX) with an Outperform rating and a $43 price target.

Credit Suisse said, "Genomic Health's stock has steadily appreciated over the past two years due to the success of its Oncotype DX cancer assays. We believe that the trend should continue as the company captures incremental market share with its already-established tests in breast and colon cancer and launches tests in new markets such as prostate cancer."

Genomic Health closed at $36.15 on Monday.

Latest Ratings for GHDX

Aug 2015Raymond JamesUpgradesUnderperformMarket Perform
Aug 2015Canaccord GenuityMaintainsHold
May 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (GHDX)

Get Benzinga's Newsletters